Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nancy Lin

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Analytical Chemistry|December 2, 2004
Continuous monitoring of enzyme reactions on a microchip: application to catalytic RNA self-cleavageTracy L Paxon, Trevor S Brown, Hsiao-Yu Nancy Lin, et al.
JAMA|November 22, 2007
Using pedometers to increase physical activity and improve health: a systematic reviewDena M Bravata, Crystal Smith-Spangler, Vandana Sundaram, et al.
Pediatric Pulmonology|August 22, 2023
Eosinophilic plastic bronchitis: Case series and review of the literatureAlexander I Gipsman, Lance Feld, Brandy Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Ethics of mandatory research biopsy for correlative end points within clinical trials in oncologyJeffrey Peppercorn, Iuliana Shapira, Deborah Collyar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrheaChau Dang, Nancy Lin, Beverly Moy, et al.
The Journal of Biological Chemistry|October 12, 2024
Molecular determinants of phospholipid treatment to reduce intracellular cholesterol accumulation in NPC1 deficiencyShikun Deng, Ting-Ann Liu, Olga Ilnytska, et al.
Cancer|September 17, 2013
Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancerPatrick G Morris, Neil M Iyengar, Sujata Patil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2011
Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinibPatrick G Morris, Carol Chen, Richard Steingart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2019
RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database AnalysisSaskia Litière, Gaëlle Isaac, Elisabeth G E De Vries, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fractionPatrick G Morris, Maura Dickler, Heather L McArthur, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Analytical Chemistry|December 2, 2004
Continuous monitoring of enzyme reactions on a microchip: application to catalytic RNA self-cleavageTracy L Paxon, Trevor S Brown, Hsiao-Yu Nancy Lin, et al.
JAMA|November 22, 2007
Using pedometers to increase physical activity and improve health: a systematic reviewDena M Bravata, Crystal Smith-Spangler, Vandana Sundaram, et al.
Pediatric Pulmonology|August 22, 2023
Eosinophilic plastic bronchitis: Case series and review of the literatureAlexander I Gipsman, Lance Feld, Brandy Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Ethics of mandatory research biopsy for correlative end points within clinical trials in oncologyJeffrey Peppercorn, Iuliana Shapira, Deborah Collyar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrheaChau Dang, Nancy Lin, Beverly Moy, et al.
The Journal of Biological Chemistry|October 12, 2024
Molecular determinants of phospholipid treatment to reduce intracellular cholesterol accumulation in NPC1 deficiencyShikun Deng, Ting-Ann Liu, Olga Ilnytska, et al.
Cancer|September 17, 2013
Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancerPatrick G Morris, Neil M Iyengar, Sujata Patil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2011
Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinibPatrick G Morris, Carol Chen, Richard Steingart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2019
RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database AnalysisSaskia Litière, Gaëlle Isaac, Elisabeth G E De Vries, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fractionPatrick G Morris, Maura Dickler, Heather L McArthur, et al.
Pageof 4